Dapsone hypersensitivity syndrome
暂无分享,去创建一个
Hong Liu | Yonghu Sun | Furen Zhang | D. Naisbitt | Lele Sun | Qing Zhao
[1] Yun-Shien Lee,et al. Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity , 2022, Journal of Biomedical Science.
[2] M. Pirmohamed,et al. HLA Class II-restricted CD8+ T cells contribute to the promiscuous immune response in dapsone hypersensitive patients. , 2021, The Journal of investigative dermatology.
[3] Yen‐Hua Huang,et al. Whole Genome Sequencing Identifies Genetic Variants Associated with Co-trimoxazole Hypersensitivity in Asians. , 2020, The Journal of allergy and clinical immunology.
[4] Hye‐Ryun Kang,et al. The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses , 2020, Expert opinion on drug safety.
[5] Hong Liu,et al. Dynamic cytokine profiles combined with enzyme-linked immunospot assay are useful for immunologically confirming the dapsone hypersensitivity syndrome. , 2020, Journal of the American Academy of Dermatology.
[6] A. Irwanto,et al. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia , 2020, medRxiv.
[7] J. Muliyil,et al. Case-control study measuring the association between HLA-B*13:01 and dapsone hypersensitivity syndrome in Indian patients , 2019, Leprosy Review.
[8] Ming Li,et al. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy. , 2019, JAMA dermatology.
[9] Andrew Gibson,et al. Dapsone‐ and nitroso dapsone‐specific activation of T cells from hypersensitive patients expressing the risk allele HLA‐B*13:01 , 2019, Allergy.
[10] Ming-Tsan Liu,et al. The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. , 2018, The Journal of investigative dermatology.
[11] Hong Liu,et al. Amino Acid Variants of HLA-DRB1 Confer Susceptibility to Dapsone Hypersensitivity Syndrome in Addition to HLA-B*13:01. , 2017, The Journal of investigative dermatology.
[12] T. Mushiroda,et al. A docking model of dapsone bound to HLA-B*13:01 explains the risk of dapsone hypersensitivity syndrome. , 2017, Journal of dermatological science.
[13] C. Sukasem,et al. Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population , 2017, Pharmacogenetics and genomics.
[14] D. Naisbitt,et al. Dapsone and Nitroso Dapsone Activation of Naı̈ve T-Cells from Healthy Donors. , 2017, Chemical research in toxicology.
[15] M. Pirmohamed,et al. New Approaches to Investigate Drug-Induced Hypersensitivity. , 2017, Chemical research in toxicology.
[16] J. Tervaert,et al. Dapsone hypersensitivity syndrome not related to G6PD deficiency , 2015, BMJ Case Reports.
[17] S. Sarkar,et al. CCR10 regulates balanced maintenance and function of resident regulatory and effector T cells to promote immune homeostasis in the skin. , 2014, The Journal of allergy and clinical immunology.
[18] Xiangsheng Chen,et al. Association between HLA-B*1301 and dapsone-induced hypersensitivity reactions among leprosy patients in China. , 2013, The Journal of investigative dermatology.
[19] P. D. de Bakker,et al. HLA-B*13:01 and the dapsone hypersensitivity syndrome. , 2013, The New England journal of medicine.
[20] Liangbin Yan,et al. Dapsone hypersensitivity syndrome among leprosy patients in China. , 2012, Leprosy review.
[21] J. Schmitt,et al. Hypersensitivity reactions to dapsone: a systematic review. , 2012, Acta dermato-venereologica.
[22] Andrew R. Jones,et al. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations , 2010, Nucleic Acids Res..
[23] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[24] S. Leng,et al. HLA-B*1301 as a Biomarker for Genetic Susceptibility to Hypersensitivity Dermatitis Induced by Trichloroethylene among Workers in China , 2007, Environmental health perspectives.
[25] C. Moore,et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir , 2002, The Lancet.
[26] N. Shear,et al. Dapsone hypersensitivity syndrome. , 1996, Journal of the American Academy of Dermatology.
[27] E. Allday,et al. Toxic effects of diaminodiphenylsulphone in treatment of leprosy. , 1951, Lancet.
[28] E. Allday,et al. TOXIC EFFECTS OF DIAMINODIPHENYL-SULPHONE IN TREATMENT OF LEPROSY , 1951 .
[29] J. Lowe,et al. The chemotherapy of leprosy in Nigeria; with an appendix on glandular fever and exfoliative dermatitis precipitated by sulfones. , 1949, International journal of Leprosy.
[30] T. Kijima,et al. Dapsone hypersensitivity syndrome-related lung injury without eosinophilia in the bronchoalveolar lavage fluid. , 2015, Internal medicine.
[31] J. Richardus,et al. Increased incidence in leprosy of hypersensitivity reactions to dapsone after introduction of multidrug therapy. , 1989, Leprosy review.